Revenue doubled, EBITDAFI up 175%, NPAT down 77.5% on FY22 fair-value base

Management's disclosed underlying NPAT of $148.1m is the cleaner read on the period. PBT fell 73.9% to $44.2m on the same base effect; against Annolyse's historical baseline, the 108.4% revenue print is an unprecedented high versus a 4-period mean of 2.9%. Operating cash flow climbed to $325.1m, capex stepped up 148.9% to $647.1m (103.4% of revenue), and net debt/EBITDA reset from 10.0x to 4.3x as EBITDA recovered. A 4cps final dividend was reinstated, the first in three years.

EBITDAFI of $397.1m (+174.8%) and operating cash flow of $325.1m reflect a genuine return of travel volumes. The reported NPAT decline (-77.5%) is misleading against FY22, which carried sizeable non-cash revaluation gains; management's underlying NPAT of $148.1m is the operating read. This matters because the headline collapse will not recur if FY22 fair-value distortion was the driver.

Capex is now running ahead of revenue. Capex of $647.1m equals 103.4% of revenue, a 148.9% step-up on FY22. This drove pre-lease FCF to -$322.0m and FCF/NPAT to -745.4%. Until the investment programme moderates, free cash flow will remain materially negative regardless of EBITDAFI recovery, and incremental funding will come from the balance sheet.

The reinstated dividend is not covered by cash flow. The 4cps final equates to a 136.5% payout of reported NPAT — above Annolyse's historical range (3-period mean 9.0%) — and -18.3% of pre-lease FCF, meaning it is being funded alongside capex rather than from generated cash. This matters because dividend sustainability now depends on EBITDAFI continuing to recover faster than the capex call.

The shape of FY23 is heavily second-half weighted: HY23 contributed only 11.1% of full-year NPAT, 46.0% of revenue and 47.6% of EBITDAFI, implying a 2H run-rate near $338.1m of revenue and $208.1m of EBITDAFI. The FY24 base therefore depends on whether the 2H exit rate holds rather than averaging across a recovering 1H. With international travel still normalising, the durability of that 2H exit rate is the key unknown the release does not resolve.

OCF/EBITDA conversion of 81.9% sits at the upper edge of the supplied historical range (4-period mean 55.2%), debtor days of 9.4 are within the normal band, and the working-capital build was modest at $8.0m. The cash return reflects volume recovery rather than working-capital release or balance-sheet assistance.

The earnings result is harder to read in headline form. Reported NPAT of $43.2m is depressed by the comparison against an FY22 number lifted by non-cash revaluation gains; the underlying $148.1m figure is the more representative measure of operating profitability. ROE of 0.5% (versus 2.4% prior) reflects the same comparable distortion rather than economic deterioration. Capital allocation, however, looks stretched on a forward view: capex at 103.4% of revenue, a dividend reinstated against negative FCF, and net debt up $259.0m to $1.7b. Leverage strengthened only because EBITDA recovered, not because debt was reduced — so if EBITDA recovery slows, the 4.3x ratio will not hold.

This briefing cannot assess passenger-volume data, airline capacity commitments, the detailed underlying-profit reconciliation, or FY24 demand expectations.